Terms: = Pancreatic cancer AND CgA AND Clinical Outcome
4 results:
1. Circulating Chromogranin A as A Marker for Monitoring clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract] [Full Text] [Related]
2. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.
Gurung B; Hua X; Runske M; Bennett B; LiVolsi V; Roses R; Fraker DA; Metz DC
Cancer Biol Ther; 2015; 16(2):219-24. PubMed ID: 25482929
[TBL] [Abstract] [Full Text] [Related]
3. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract] [Full Text] [Related]
4. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
[TBL] [Abstract] [Full Text] [Related]